The FDA has conﬁrmed End-of-Phase 2 outcomes for ATH434 in Multiple System Atrophy and agreed that one pivotal Phase 3 trial plus conﬁrmatory evidence could support approval.

ATH434 - Alterity Therap

Jul 7, 2026